1. Pink Sheet
  2. >>Legislation

Biosimilars Could Give Brands the Boot Mid-Year Under Amendment Added to Senate PBM Reform Bill

 
• By Sarah Karlin-Smith

However, the low CBO score attached to the measure may suggest PBMs might not be incentivized to follow through on the congressional permission.

legs up in air with colorful cowboy coots in kicking motion
A measure to facilitate faster biosimilar coverage was added to the Senate Finance Committee PBM package. • Source: Shutterstock

Medicare Part D plans could switch the coverage status of a reference biologic midyear if the plan adds a biosimilar for that product to the formulary, under an amendment added to the Senate Finance Committee’s pharmacy benefit manager reform package, which cleared the committee on a 26-1 vote 26 July.

The amendment from Sens. Debbie Stabenow, D-MI, and James Lankford, R-OK, was added to the chairman’s mark of the Modernizing and Ensuring PBM Accountability (MEPA) Act ahead of the markup.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

UroGen’s Bladder Cancer Drug Draws Split Decision From US FDA Panel

 
• By Sue Sutter

The Oncologic Drugs Advisory Committee voted 5-4 that the overall benefit-risk of UGN-102 is not favorable in patients with recurrent low grade, intermediate-risk, non-muscle invasive bladder cancer and also divided on whether randomized trials should be required for future development programs.

US FDA Will Help States Apply To Import Cheaper Drugs From Canada

 
• By Cathy Kelly

The FDA is not currently signaling that stringent rules for the process will be relaxed, but the agency's change in approach is notable.

Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits Out

 
• By Neena Brizmohun

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.